Pretreatment density or effective score of PD-1+CD8+ T cells predicted response to immune-combination therapy.42,43 This study further underscored the predictive value of PD-1+CD8+ T cells as biomarkers for immunotherapy durable efficacy in AFP-G/GEJ adenocarcinoma. The gene discussed is CD8A; the disease is gastroesophageal junction adenocarcinoma.